These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36366568)

  • 1. Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2.
    Nakanishi A; Okumura H; Hashita T; Yamashita A; Nishimura Y; Watanabe C; Kamimura S; Hayashi S; Murakami S; Ito K; Iwao T; Ikeda A; Hirose T; Sunazuka T; Tanaka Y; Matsunaga T
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Novel vector preS1-tp fusion protein effectively inhibits hepatitis B virus replication and cccDNA synthesis by mediating hepatitis B virus targeting sequence small interfering RNA].
    Zeng YL; Gao F; Zhang C; Wei JF; Ma L; Ding GG; Li W; Shang J; Kang Y
    Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):126-132. PubMed ID: 33685080
    [No Abstract]   [Full Text] [Related]  

  • 3. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
    Sheraz M; Cheng J; Tang L; Chang J; Guo JT
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels.
    Ko C; Chakraborty A; Chou WM; Hasreiter J; Wettengel JM; Stadler D; Bester R; Asen T; Zhang K; Wisskirchen K; McKeating JA; Ryu WS; Protzer U
    J Hepatol; 2018 Dec; 69(6):1231-1241. PubMed ID: 30142426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
    Allweiss L; Volz T; Giersch K; Kah J; Raffa G; Petersen J; Lohse AW; Beninati C; Pollicino T; Urban S; Lütgehetmann M; Dandri M
    Gut; 2018 Mar; 67(3):542-552. PubMed ID: 28428345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection.
    Guner R; Karahocagil M; Buyukberber M; Kandemir O; Ural O; Usluer G; Inan D; Koksal I; Baykam N; Hizel K; Yamazhan T; Esen S; Tasyaran MA
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1185-91. PubMed ID: 21934508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy.
    Murai K; Kodama T; Hikita H; Shimoda A; Fukuoka M; Fukutomi K; Shigeno S; Shiode Y; Motooka D; Higuchi Y; Miyakawa K; Suemizu H; Ryo A; Tahata Y; Makino Y; Yamada R; Sakamori R; Tatsumi T; Takehara T
    Hepatol Commun; 2022 Sep; 6(9):2474-2487. PubMed ID: 35608131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The specific core fucose-binding lectin Pholiota squarrosa lectin (PhoSL) inhibits hepatitis B virus infection in vitro.
    Ouchida T; Maeda H; Akamatsu Y; Maeda M; Takamatsu S; Kondo J; Misaki R; Kamada Y; Ueda M; Ueda K; Miyoshi E
    Sci Rep; 2023 Apr; 13(1):6175. PubMed ID: 37061516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic Analysis of Nuclear Hepatitis B Virus Relaxed Circular DNA-Associated Proteins Identifies UV-Damaged DNA Binding Protein as a Host Factor Involved in Covalently Closed Circular DNA Formation.
    Marchetti AL; Zhang H; Kim ES; Yu X; Jang S; Wang M; Guo H
    J Virol; 2022 Jan; 96(2):e0136021. PubMed ID: 34705558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals.
    Huang H; Wang J; Li W; Chen R; Chen X; Zhang F; Xu D; Lu F
    J Clin Virol; 2018; 99-100():71-78. PubMed ID: 29353073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
    Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
    Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forkhead O Transcription Factor 4 Restricts HBV Covalently Closed Circular DNA Transcription and HBV Replication through Genetic Downregulation of Hepatocyte Nuclear Factor 4 Alpha and Epigenetic Suppression of Covalently Closed Circular DNA via Interacting with Promyelocytic Leukemia Protein.
    Li Y; He M; Gong R; Wang Z; Lu L; Peng S; Duan Z; Feng Y; Liu Y; Gao B
    J Virol; 2022 Jul; 96(13):e0054622. PubMed ID: 35695580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of siRNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cell.
    Xin XM; Li GQ; Guan XR; Li D; Xu WZ; Jin YY; Gu HX
    Hepatogastroenterology; 2008; 55(88):2178-83. PubMed ID: 19260501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis.
    Wong DK; Cheng SCY; Mak LL; To EW; Lo RC; Cheung TT; Seto WK; Fung J; Man K; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2020 Feb; 18(2):449-456. PubMed ID: 31252193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
    Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
    Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
    Iwamoto M; Watashi K; Tsukuda S; Aly HH; Fukasawa M; Fujimoto A; Suzuki R; Aizaki H; Ito T; Koiwai O; Kusuhara H; Wakita T
    Biochem Biophys Res Commun; 2014 Jan; 443(3):808-13. PubMed ID: 24342612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation.
    Wei ZQ; Zhang YH; Ke CZ; Chen HX; Ren P; He YL; Hu P; Ma DQ; Luo J; Meng ZJ
    World J Gastroenterol; 2017 Sep; 23(34):6252-6260. PubMed ID: 28974891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells.
    Zhao K; Guo F; Wang J; Zhong Y; Yi J; Teng Y; Xu Z; Zhao L; Li A; Wang Z; Chen X; Cheng X; Xia Y
    Hepatology; 2023 Apr; 77(4):1366-1381. PubMed ID: 35718932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes.
    Lempp FA; Wiedtke E; Qu B; Roques P; Chemin I; Vondran FWR; Le Grand R; Grimm D; Urban S
    Hepatology; 2017 Sep; 66(3):703-716. PubMed ID: 28195359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.